2379-61-5

Usage

Uses

Used in Pesticide Applications:
2,3-Dichloro-6,7-dinitroquinoxaline is used as a pesticide for its effectiveness in controlling and eliminating a wide range of pests. It targets the biochemical pathways of these organisms, leading to their death and providing protection to crops and other plants.
Used in Herbicide Applications:
In the agricultural industry, 2,3-Dichloro-6,7-dinitroquinoxaline is utilized as a herbicide to inhibit the growth of unwanted plants. Its disruptive action on the biochemical processes of these plants helps maintain the health and productivity of cultivated fields and gardens.
Safety Precautions:
Due to the highly toxic and reactive nature of 2,3-Dichloro-6,7-dinitroquinoxaline, it is crucial to handle 2,3-DICHLORO-6,7-DINITROQUINOXALINE with extreme care. It should only be used in controlled environments and with proper safety measures in place to minimize the risk of exposure and potential harm to humans, animals, and the environment.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 114828-89-6 6,7-dinitroquinoxaline-2,3-dione 
• 15804-19-0 2,3-dihydroxyquinoxaline 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 2379-56-8 2,3-dihydroxy-6-nitroquinoxaline 
• 2379-57-9 6,7-dinitro-2,3-dihydroxyquinoxaline 
• 2379-57-9 6,7-dinitroquinoxaline-2,3(1H,4H)-dione 

Downstream Products

• 31639-73-3 3-chloro-8,9-dinitro-12H-benzo[5,6][1,4]thiazino[2,3-b]quinoxaline 

Relevant academic research and scientific papers

Novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and preparation and application thereof

The invention provides a novel molecular targeting anti-tumor aza-steroid derivative based on lipid toxicity and a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound as shown in a formula I, or a salt thereof, or a stereoisomer thereof. The compound is low in toxicity or basically non-toxic to normal cells, has an obvious inhibition effect to tumor cell lines, particularly has good lipid toxicity selectivity to tumor cells such as liver cancer, lung cancer and the like in vivo, and has an obvious inhibition effect; meanwhile, the compound can effectively activate SREBP1 and PPAR gamma, inhibit lipid transport MTTP, cause lipid aggregation in tumor cells and cause lipid toxicity of the tumor cells. The compound can be used for treating liver cancer, lung cancer and the like in a molecular targeting manner, is low in toxicity or even non-toxic, and has a good application prospect.

Synthesis and pharmacological activity of certain thiadiazolo [2',3':2,3] imidazo [4,5-B] quinoxalines

Derivatives of thiadiazolo [2',3':2,3] imidazo [4,5-b] quinoxalines were synthesized by the reaction of 5-substituted-1,3,4-thiadiazol-2-amine with 2,3-dichloro-6,7- dinitroquinoxalines. The synthesized compounds were characterized by using spectral data. They were then screened for analgesic, anti-inflammatory and ulcerogenic activity.

Synthesis of a Zn-salen resorcinarene-based cavitand and its fluorescence response to nitro compounds

The synthesis, spectroscopic characterisation, conformational switching and fluorescence quenching efficiency of a resorcinarene-based cavitand containing Zn-salen (Zn-Cav) are reported. Synthesis of Zn-Cav was accomplished by the condensation of a quinoxaline derivatised with Zn-salen and a resorcinarene-based cavitand containing three quinoxalines. 1H NMR spectroscopy confirmed that in DMSO, chloroform and acetone Zn-Cav resides in the vase conformation. The molecular geometry of Zn-Cav selectively changes from vase to kite under acidic conditions. Detection by fluorescence quenching of nitro-containing molecules, such as 4-nitrotoluene, 2,4-dinitrotoluene and 2,3-dimethyl-2,3-dinitrobutane was explored by spectrofluorimetry. It was found that the fluorescence of Zn-Cav is efficiently quenched by nitroaromatic compounds.

Synthesis of 2,3-dichloroquinoxalines via vilsmeier reagent chlorination

A convenient and high-yielding synthesis of 2,3-dichloroquinoxalines from the corresponding 2,3- dihydroxyquinoxalines has been developed. Treatment of a slurry of the 2,3-dihydroxyquinoxaline 1a-j with N,N-dimethylformamide in the presence of excess thionylchloride in 1,2-dichloroethane results in the rapid and high-yielding formation of the 2,3-dichloroquinoxaline derivatives 2a-j. Simplified workup and purification procedures for these compounds are also described.

NON-PEPTIDE GLP-1 AGONISTS

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an ac

Synthesis and Fungicidal Activity of 1,4-Dithiino[2,3-b]quinoxaline-2,3-dicarbonitriles

A series of eleven 1,4-dithiino[2,3-b]quinoxaline-2,3-dicarbonitriles was prepared by reaction of 2,3-dichloroquinoxalines with disodium (Z)-2,3-dimercapto-2-butenedinitrile in N,N-dimethylformamide. These products were tested for in-vitro fungicidal activity by a Minimum Inhibitory Concentration (MIC) method. Several of these compounds showed broad-spectrum fungicidal activity. The activity exhibited by these compounds was greatly dependent upon the substituents of the quinoxaline ring, with the nitro-substituted derivatives showing the higest levels of antifungal activity. None of the compounds prepared, however, showed fungicidal activity comparable to that of the commercial fungicides screened.

Synthesis and Biological Activities of Some 1,5-Dihydroditriazolo-quinoxaline-1,6-diones

Some new 1,5-dihydroditriazoloquinoxaline-1,6-diones (IV) have been prepared and tested for their antiallergic, antimicrobial, antiprotozoal and anthelmintic activities.Compounds IVe,d,f are found to posess promising egg albumin-induced rat passive cutaneous anaphylaxis (PCA) activity by showing more than 90percent inhibition at 50 mg/kg dose